EVA: Evista Alendronate Comparison

Lilly

Status and phase: Completed; Phase 4

Conditions: Osteoporosis

Treatments: Drug: raloxifene HCI and alendronate Na

Study type: Interventional

Funder types: Industry

Identifiers

NCT00035971

5548

H3S-US-GGKO

Details and patient eligibility

About

The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures

Sex: Female

Ages: 50 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• 50-80 years of age, inclusive
• 2 years since last menses
• Dx femoral neck osteoporosis
• No vertebral fractures

Exclusion Criteria

• Poor candidate for study drugs
• Hx of diseases affecting bone metabolism
• Hx of breast/estrogen-dependent cancer
• Current use of osteoporosis drug therapy
• Hx/high risk of VTE